Clinical trials: sponsored by Canadian Cancer Trials Group
Breast Cancer
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
- Trial name
- FINER (NCT04650581)
- Testing
- Ipatasertib, Fulvestrant
- Where
- 39 sites in Australia, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing…
- Trial name
- NCT02630693
- Testing
- Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor
- Where
- 22 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
This research is being done because investigators involved in this study would like to compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy boost to see which treatment is better and what the…
- Trial name
- NCT01982786
- Testing
- Image guided external beam radiotherapy with or without brachytherapy boost, Brachytherapy
- Where
- 9 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Canadian Cancer Trials Group
Rectal Cancer
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer.
- Trial name
- NCT03259035
- Testing
- Folfox Protocol, Capox
- Where
- 11 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.
- Trial name
- NCT04663997
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066443
- Testing
- pegfilgrastim, docetaxel, epirubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 93 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer.
- Trial name
- NCT03568422
- Testing
- CFI-402257, Paclitaxel
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Canadian Cancer Trials Group
Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type…
- Trial name
- NCT01846390
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 6 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma, Non-Hodgkin, Multiple Myeloma
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- CAPTUR (NCT03297606)
- Testing
- Olaparib, Dasatinib, Nivolumab plus Ipilimumab
- Where
- 10 sites in Canada
- Volunteers
- 720 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer Metastatic
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to…
- Trial name
- PLATON (NCT03784755)
- Testing
- Ablative Radiation Therapy, Standard of care
- Where
- 18 sites in Canada
- Volunteers
- 409 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, and prednisone, work in different ways to stop…
- Trial name
- NCT00428142
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 19 sites in Canada
- Volunteers
- 95 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
Solid Malignancies
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
The purpose of this study is to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects…
- Trial name
- NCT02537418
- Testing
- durvalumab, tremelimumab
- Where
- 7 sites in Canada
- Volunteers
- 153 people
- Sponsor
- Canadian Cancer Trials Group
Oropharyngeal Squamous Cell Carcinoma
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back.
- Trial name
- NCT03410615
- Testing
- Radiation, Cisplatin, Durvalumab
- Where
- 26 sites in Belgium, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib.
- Trial name
- NCT02905318
- Testing
- Palbociclib
- Where
- 7 sites in Canada
- Volunteers
- 19 people
- Sponsor
- Canadian Cancer Trials Group
Advanced/Metastatic Solid Tumours
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
This research is being done because these viruses have been shown to shrink tumours in animals and human tumour samples by selectively killing cancer cells and creating an immune response to the tumour antigen contained in the…
- Trial name
- NCT02285816
- Testing
- MG1MA3, AdMA3
- Where
- 4 sites in Canada
- Volunteers
- 56 people
- Sponsor
- Canadian Cancer Trials Group
Cervix Neoplasms
Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels
The aim of this study is to measure the oxygen content and interstitial fluid pressure in cervix cancer patients. Tumour oxygen content and internal pressure of tumours may be an important factor that influences the effectiveness…
- Trial name
- NCT00188539
- Testing
- Pre-treatment tumour oxygen measurements (under anesthesia)
- Where
- Canada
- Volunteers
- 346 people
- Sponsor
- University Health Network, Toronto
Ductal Breast Carcinoma, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy.
- Conditions
- Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma
- Trial name
- NCT03414970
- Testing
- Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment
- Where
- 859 sites in United States, Canada
- Volunteers
- 898 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
- Trial name
- NCT04176848
- Testing
- CFI-400945, Durvalumab
- Where
- 5 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Oropharyngeal Cancer
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
- Trial name
- EVADER (NCT03822897)
- Testing
- Radiation, Cisplatin
- Where
- 14 sites in Canada
- Volunteers
- 103 people
- Sponsor
- Canadian Cancer Trials Group